Recent Company News

• 01:02 AM ET Jul 01, 2025
  

  Galderma Group announced that Thomas Dittrich, CFO, will be leaving the company (CHF 115.00, 0.00)

• 01:08 AM ET Jun 25, 2025
  

  Galderma Group initiates two new clinical trials investigating nemolizumab in patients with systemic sclerosis and chronic pruritus of unknown origin (CHF 111.30, 0.00)

• 02:49 AM ET Jun 06, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:02 AM ET Jun 18, 2025
  

  Galderma announces new data demonstrating Nemluvio's (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years (CHF 108.10, 0.00)

• 06:16 AM ET Jun 12, 2025
  

  Galderma's nemluvio receives UK's NICE recommendation for moderate-to-severe atopic dermatitis (CHF 112.60, -1.20)

• 07:38 AM ET Jun 06, 2025
  

  Energy, Healthcare and Retail lead; Basic Resources, Industrial Goods/Services and Consumer Products/Services lag:

• 01:43 AM ET Jun 06, 2025
  

  Galderma Group initiated buy at Kepler Cheuvreux (CHF 113.30, 0.00)

• 01:04 AM ET Jun 06, 2025
  

  Galderma announces new interim two-year data from an extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis (CHF 113.30, 0.00)

• 11:31 AM ET Jun 03, 2025
  

  EQT completes sale of shares in Galderma Group AG (CHF 111.20, 0.00)